4D Molecular Therapeutics Inc
FDMT10.500USD
-0.420-3.85%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
490.35MMarket Cap
LossP/E TTM
More Details of 4D Molecular Therapeutics Inc Company
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
4D Molecular Therapeutics Inc Info
Ticker SymbolFDMT
Company name4D Molecular Therapeutics Inc
IPO dateDec 11, 2020
CEODr. David Kirn, M.D.
Number of employees227
Security typeOrdinary Share
Fiscal year-endDec 11
Address5858 Horton Street #455
CityEMERYVILLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94608
Phone15105052680
Websitehttps://4dmoleculartherapeutics.com/
Ticker SymbolFDMT
IPO dateDec 11, 2020
CEODr. David Kirn, M.D.
Company Executives of 4D Molecular Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Mr. Ashoo Gupta
Mr. Ashoo Gupta
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
45.66K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Simms
Mr. Christopher (Chris) Simms
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Mr. Ashoo Gupta
Mr. Ashoo Gupta
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
45.66K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
15.00K
0.00%
Netherlands
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Nov 8
Updated: Sat, Nov 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
Novo Holdings A/S
6.80%
BlackRock Institutional Trust Company, N.A.
6.67%
Other
58.84%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
Novo Holdings A/S
6.80%
BlackRock Institutional Trust Company, N.A.
6.67%
Other
58.84%
Shareholder Types
Shareholders
Proportion
Investment Advisor
19.79%
Investment Advisor/Hedge Fund
19.57%
Hedge Fund
17.68%
Venture Capital
17.25%
Research Firm
14.76%
Individual Investor
3.95%
Pension Fund
0.15%
Sovereign Wealth Fund
0.12%
Bank and Trust
0.11%
Other
6.63%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
353
39.94M
73.19%
-18.33M
2025Q2
351
46.37M
100.09%
-13.01M
2025Q1
358
46.38M
99.71%
-13.16M
2024Q4
357
49.60M
107.13%
-13.93M
2024Q3
350
60.77M
117.85%
-4.39M
2024Q2
340
60.30M
117.01%
-2.54M
2024Q1
324
59.47M
116.84%
+10.27M
2023Q4
284
45.54M
106.82%
-1.53M
2023Q3
275
45.63M
108.12%
-4.94M
2023Q2
263
44.82M
109.79%
-393.70K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
4.63M
9.91%
+68.00K
+1.49%
Jun 30, 2025
RA Capital Management, LP
4.56M
9.77%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
3.74M
8.01%
-7.99K
-0.21%
Jun 30, 2025
Novo Holdings A/S
2.00M
4.28%
+50.00K
+2.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
6.67%
-415.30K
-11.76%
Jun 30, 2025
The Vanguard Group, Inc.
2.74M
5.86%
-20.82K
-0.75%
Jun 30, 2025
Janus Henderson Investors
1.75M
3.76%
-137.53K
-7.27%
Jun 30, 2025
Kirn (David)
1.66M
3.55%
-360.00
-0.02%
Apr 24, 2025
Federated MDTA LLC
1.65M
3.54%
+411.45K
+33.10%
Jun 30, 2025
Millennium Management LLC
1.48M
3.18%
-150.26K
-9.20%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Federated Hermes MDT Small Cap Core ETF
0.59%
iShares Micro-Cap ETF
0.07%
Harbor Human Capital Factor US Small Cap ETF
0.07%
iShares Health Innovation Active ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
View more
Federated Hermes MDT Small Cap Core ETF
Proportion0.59%
iShares Micro-Cap ETF
Proportion0.07%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.07%
iShares Health Innovation Active ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
